vorasidenib
servier
['vorasidenib', 'indigo', 'faron']
exciting news from #asco23. the phase iii indigo trial demonstrated very promising results. if approved, the drug vorasidenib could become a new standard of care for patients with grade 2 idh mutant oligodendrogliomas and astrocytomas. 
CEO @NBTStweets. 
Tweets=my own. RT≠endorsement.